PRIC285 Inhibitors
PRIC285 inhibitors constitute a diverse array of chemicals targeting key signaling pathways crucial for cellular processes. XMD8-92, a pan-RAF kinase inhibitor, disrupts the RAF-MEK-ERK signaling axis, indirectly impacting PRIC285 through altered MAPK signaling. This influences PRIC285-associated processes related to cellular proliferation and survival. BAY 61-3606, a Syk inhibitor, modulates immune response signaling, indirectly affecting PRIC285 by altering pathways related to immune modulation and inflammation. GSK1120212, a MEK1/2 inhibitor, disrupts the MAPK pathway, influencing PRIC285-associated processes linked to cell proliferation and survival. PF-3758309, an Akt inhibitor, modulates the PI3K-Akt-mTOR pathway, impacting PRIC285 through altered downstream signaling related to cell survival and proliferation.
Dasatinib, a dual BCR-ABL and Src family kinase inhibitor, modulates tyrosine kinase signaling, indirectly influencing PRIC285-associated processes related to cell proliferation and survival. AZD5363, another Akt inhibitor, affects the PI3K-Akt-mTOR pathway, impacting PRIC285-related cellular processes. Vemurafenib, a BRAF inhibitor, disrupts the RAF-MEK-ERK signaling pathway, indirectly affecting PRIC285 through altered MAPK signaling crucial for cellular proliferation and survival. BIX 02188, a MEK5/ERK5 inhibitor, disrupts the MEK5-ERK5 pathway, influencing PRIC285-associated processes related to cell proliferation and survival. PIK-75, a PI3K inhibitor, modulates the PI3K-Akt-mTOR signaling pathway, impacting PRIC285 through altered downstream signaling events related to cell survival and proliferation. Tofacitinib, a JAK inhibitor, modulates JAK-STAT signaling, indirectly affecting PRIC285-associated processes related to inflammation and immune response. SCH772984, an ERK inhibitor, disrupts the RAF-MEK-ERK signaling pathway, indirectly influencing PRIC285 through altered MAPK signaling. Lastly, AZD8055, an mTOR inhibitor, modulates the PI3K-Akt-mTOR pathway, impacting PRIC285 through altered downstream signaling crucial for cellular survival and proliferation. This diverse set of inhibitors offers valuable tools for investigating PRIC285's intricate regulatory networks and its role in cellular processes critical for various pathological conditions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
XMD 8-92 (free base) | 1234480-50-2 | sc-364068 sc-364068A sc-364068B sc-364068C | 5 mg 10 mg 100 mg 1 g | $235.00 $340.00 $1700.00 $10330.00 | 10 | |
XMD8-92, a pan-RAF kinase inhibitor, disrupts the RAF-MEK-ERK signaling pathway. By targeting RAF kinases, it modulates the MAPK pathway, indirectly impacting PRIC285 through altered downstream signaling. This influences PRIC285-associated processes related to cellular proliferation and survival. | ||||||
BAY 61-3606 | sc-507485 | 2 mg | $345.00 | 1 | ||
BAY 61-3606, a Syk inhibitor, modulates immune response signaling. Its influence on Syk-mediated pathways indirectly affects PRIC285 by altering signaling cascades related to immune modulation, impacting PRIC285-associated processes related to inflammation and cellular interactions. | ||||||
PF-3758309 | 898044-15-0 | sc-478493 | 10 mg | $260.00 | ||
PF-3758309, an Akt inhibitor, modulates the PI3K-Akt-mTOR signaling pathway. Its influence on Akt-mediated pathways indirectly affects PRIC285 by altering downstream signaling events, impacting PRIC285-associated processes related to cell survival and proliferation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a dual BCR-ABL and Src family kinase inhibitor, modulates tyrosine kinase signaling. Its impact on Src family kinases indirectly influences PRIC285 by altering downstream signaling events, impacting PRIC285-associated processes related to cell proliferation and survival. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an Akt inhibitor, modulates the PI3K-Akt-mTOR signaling pathway. Its influence on Akt-mediated pathways indirectly affects PRIC285 by altering downstream signaling events, impacting PRIC285-associated processes related to cell survival and proliferation. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib, a BRAF inhibitor, disrupts the RAF-MEK-ERK signaling pathway. By targeting BRAF, it modulates the MAPK pathway, indirectly impacting PRIC285 through altered downstream signaling. This influences PRIC285-associated processes related to cellular proliferation and survival. | ||||||
BIX02188 | 1094614-84-2 | sc-503854 | 10 mg | $380.00 | ||
BIX 02188, a MEK5/ERK5 inhibitor, disrupts the MEK5-ERK5 signaling pathway. Its impact on ERK5-mediated signaling indirectly influences PRIC285 by altering downstream events, impacting PRIC285-associated processes related to cell proliferation and survival. | ||||||
PIK-75, hydrochloride | 372196-77-5 | sc-296089 sc-296089A | 1 mg 5 mg | $29.00 $124.00 | ||
PIK-75, a PI3K inhibitor, modulates the PI3K-Akt-mTOR signaling pathway. Its influence on PI3K-mediated pathways indirectly affects PRIC285 by altering downstream signaling events, impacting PRIC285-associated processes related to cell survival and proliferation. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
SCH772984, a ERK inhibitor, disrupts the RAF-MEK-ERK signaling pathway. Its impact on ERK-mediated signaling indirectly influences PRIC285 through altered downstream events, impacting PRIC285-associated processes related to cellular proliferation and survival. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055, an mTOR inhibitor, modulates the PI3K-Akt-mTOR signaling pathway. Its influence on mTOR-mediated pathways indirectly affects PRIC285 by altering downstream signaling events, impacting PRIC285-associated processes related to cell survival and proliferation. | ||||||